Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Abhishek D. Garg(KU Leuven), Lorenzo Galluzzi(Délégation Paris 5), Lionel Apétoh(Inserm), Thaïs Baert(Universitair Ziekenhuis Leuven), Raymond B. Birge(Rutgers, The State University of New Jersey), José Manuel Bravo‐San Pedro(Délégation Paris 5), Karine Breckpot(Vrije Universiteit Brussel), David Brough(University of Manchester), Ricardo A. Chaurio(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mara Cirone(Sapienza University of Rome), An Coosemans(Universitair Ziekenhuis Leuven), Pierre G. Coulie(de Duve Institute), Dirk De Ruysscher(KU Leuven), Luciana Dini(University of Salento), Peter de Witte(KU Leuven), Aleksandra M. Dudek-Perić(KU Leuven), Alberto Faggioni(Sapienza University of Rome), Jitka Fučíková(Charles University), Udo S. Gaipl(Universitätsklinikum Erlangen), Jakub Gołąb(Medical University of Warsaw), Marie-Lise Gougeon(Institut Pasteur), Michael R. Hamblin(Massachusetts General Hospital), Akseli Hemminki(University of Helsinki), Martin Herrmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), James W. Hodge(National Institutes of Health), Oliver Kepp(Délégation Paris 5), Guido Kroemer(Délégation Paris 5), Dmitri V. Krysko(Ghent University), W. Land(Inserm), Frank Madeo(University of Graz), Angelo A. Manfredi(Vita-Salute San Raffaele University), Stephen R. Mattarollo(Translational Research Institute), Christian Maueröder(Friedrich-Alexander-Universität Erlangen-Nürnberg), Nicolò Merendino(Università degli Studi della Tuscia), Gabriele Multhoff(TUM Klinikum), Thomas Pabst(University Hospital of Bern), Jean‐Ehrland Ricci(Inserm), Chiara Riganti(University of Turin), Erminia Romano(KU Leuven), Nicole Rufo(KU Leuven), Mark J. Smyth(The University of Queensland), Jürgen Sonnemann(Jena University Hospital), Radek Špíšek(Charles University), John Stagg(Centre Hospitalier de l’Université de Montréal), Erika Vacchelli(Délégation Paris 5), Peter Vandenabeele(Ghent University), Lien Vandenberk(KU Leuven), Benoı̂t J. Van den Eynde(Ludwig Cancer Research), Stefaan Van Gool(KU Leuven), Francesca Velotti(Università degli Studi della Tuscia), Laurence Zitvogel(Université Paris-Sud), Patrizia Agostinis(KU Leuven)
Frontiers in Immunology
November 20, 2015
Cited by 392Open Access
Full Text

Abstract

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.


Related Papers

No related papers found

Powered by citation graph analysis